Question-and-Answer Session
Operator
(Operator Instructions). We'll take our first question from John Gordon with Deltec Asset Management.
John Gordon - Deltec Asset Management
Carl, thank you very much for a clear and dynamic presentation. I have a couple of questions. The first is just to clear up something that you just said about the $11 million expenses for the Phase 3 PHN trial, and $11 million for Phase 3 hot flashes. I don't recall hearing you saying that you would initiate anything with respect to hot flashes this year. I just heard something about hoping to have a partner by the end of the year. Is there actually going to be an initiation of a Phase 3 for hot flashes in '08?
Carl Pelzel
Yes, John, good question. Maybe I should clarify that in the presentation. As I did mention, we have started the PHN trial. We haven't even had our discussion with the FDA on what trials would be necessary for hot flash, and our discussions with partners are going exceedingly well, especially after we launched the data.
But I felt, in order to present the most conservative view to our investors, I would need to put those costs out there. It is not my objective to start that hot flash trial, given our current cash position. So the reason for including it is just to present the most conservative view as we can possibly on our expenses and cash position.
John Gordon - Deltec Asset Management
Okay. And then, just again, related to sort of financial considerations for this year as it relates to GLUMETZA, I'm assuming that your $24 million to $28 million of G&A expenses does not include anything for product cost for GLUMETZA?
Carl Pelzel
John, it does include, again, we are taking a very conservative approach, it does include some minimal costs to maintain the temporary sales force through June, July. I think it's very possible that we'll have a deal before then. And, as I think I've mentioned before, we have the ability to discontinue the services of that sales organization as soon as we need to. So there are some minimal expenses in that SG&A number that relate to marketing, as well as this contract sales organization.
John Gordon - Deltec Asset Management
Right. But I take it that you are not giving any guidance with respect to GLUMETZA operating profit or revenues for this year?
- To read the full transcript on Seeking Alpha, click here »
